Last reviewed · How we verify

Fentanyl Plus Midazolam

Mount Carmel Health System · FDA-approved active Small molecule

Fentanyl is an opioid agonist that binds mu receptors to provide analgesia and sedation, while midazolam is a benzodiazepine that enhances GABAergic inhibition in the central nervous system for anxiolysis and sedation.

Fentanyl is an opioid agonist that binds mu receptors to provide analgesia and sedation, while midazolam is a benzodiazepine that enhances GABAergic inhibition in the central nervous system for anxiolysis and sedation. Used for Procedural sedation and analgesia, Palliative care and pain management.

At a glance

Generic nameFentanyl Plus Midazolam
Also known asSublimaze, Versed
SponsorMount Carmel Health System
Drug classOpioid agonist + benzodiazepine combination
TargetMu opioid receptor (fentanyl); GABA-A receptor (midazolam)
ModalitySmall molecule
Therapeutic areaAnesthesia, Analgesia, Palliative Care
PhaseFDA-approved

Mechanism of action

Fentanyl acts as a potent mu-opioid receptor agonist, blocking pain signal transmission and producing analgesia and respiratory depression. Midazolam potentiates inhibitory GABA neurotransmission, producing anxiolytic, sedative, and amnestic effects. Together, this combination provides enhanced analgesia and sedation for procedural or palliative use.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: